16.09

1.39% 0.22

Pre-market: 16.20 0.11 +0.68%

Sarepta Therapeutics Inc (SRPT)

Overview News Price History Option Chain Financials Why SRPT Down? Discussions Forecast Stock Split

Sarepta Therapeutics Inc stock is traded at $16.09, with a volume of 2.07M. It is up +1.39% in the last 24 hours and down -18.45% over the past month. Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Previous Close:

$15.87

Open:

$16.08

24h Volume:

2.07M

Relative Volume:

0.74

Market Cap:

$1.69B

Revenue:

$2.48B

Net Income/Loss:

$-57.96M

P/E Ratio:

-21.21

EPS:

-0.7585

Net Cash Flow:

$-453.97M

1W Performance:

-15.18%

1M Performance:

-18.45%

6M Performance:

-12.84%

1Y Performance:

-84.36%

1-Day Range:

$15.70

$16.43

1-Week Range:

$15.70

$17.89

52-Week Range:

$10.41

$107.77

Sarepta Therapeutics Inc Stock (SRPT) Company Profile

Name

Sarepta Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

617-274-4000

Address

215 FIRST STREET, CAMBRIDGE, MA

Employee

1,372

Twitter

@sarepta

Next Earnings Date

2025-08-01

Latest SEC Filings

SRPT's Discussions on Twitter

Compare SRPT vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SRPT Sarepta Therapeutics Inc	16.09	1.66B	2.48B	-57.96M	-453.97M	-0.7585
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Resumed	Barclays	Equal Weight
Dec-09-25	Initiated	Wedbush	Outperform
Nov-05-25	Upgrade	Mizuho	Neutral → Outperform
Sep-22-25	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jul-29-25	Upgrade	Barclays	Underweight → Equal Weight
Jul-29-25	Initiated	Bernstein	Mkt Perform
Jul-29-25	Reiterated	H.C. Wainwright	Sell
Jul-29-25	Upgrade	JP Morgan	Underweight → Neutral
Jul-29-25	Upgrade	Oppenheimer	Perform → Outperform
Jul-28-25	Downgrade	Barclays	Equal Weight → Underweight
Jul-25-25	Downgrade	JP Morgan	Neutral → Underweight
Jul-24-25	Initiated	Citigroup	Sell
Jul-23-25	Downgrade	BofA Securities	Neutral → Underperform
Jul-22-25	Downgrade	Barclays	Overweight → Equal Weight
Jul-21-25	Downgrade	Deutsche Bank	Buy → Hold
Jul-21-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-21-25	Downgrade	Mizuho	Outperform → Neutral
Jul-21-25	Downgrade	Needham	Hold → Underperform
Jul-21-25	Downgrade	UBS	Buy → Neutral
Jul-18-25	Downgrade	Needham	Buy → Hold
Jun-20-25	Downgrade	William Blair	Outperform → Mkt Perform
Jun-18-25	Downgrade	TD Cowen	Buy → Hold
Jun-17-25	Initiated	Wolfe Research	Peer Perform
Jun-16-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jun-16-25	Downgrade	BofA Securities	Buy → Neutral
Jun-16-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jun-16-25	Downgrade	H.C. Wainwright	Neutral → Sell
Jun-16-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-16-25	Downgrade	Piper Sandler	Overweight → Neutral
Jun-06-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform
May-08-25	Downgrade	Evercore ISI	Outperform → In-line
Apr-11-25	Initiated	Wells Fargo	Overweight
Apr-02-25	Upgrade	H.C. Wainwright	Sell → Neutral
Mar-31-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Feb-11-25	Initiated	Deutsche Bank	Hold
Nov-27-24	Reiterated	Needham	Buy
Nov-25-24	Initiated	H.C. Wainwright	Sell
Nov-07-24	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Oct-21-24	Initiated	Jefferies	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Jul-29-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jun-26-24	Downgrade	Citigroup	Buy → Neutral
May-31-24	Initiated	Piper Sandler	Overweight
May-28-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
May-14-24	Upgrade	Oppenheimer	Perform → Outperform
Jan-31-24	Initiated	BMO Capital Markets	Outperform
Dec-13-23	Resumed	Citigroup	Buy
Dec-12-23	Initiated	Deutsche Bank	Buy
Nov-21-23	Initiated	Wedbush	Outperform
Oct-31-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-31-23	Downgrade	Oppenheimer	Outperform → Perform
Jun-23-23	Downgrade	Evercore ISI	Outperform → In-line
Apr-26-23	Initiated	SMBC Nikko	Outperform
Apr-04-23	Initiated	Citigroup	Buy
Mar-01-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-22-22	Reiterated	BTIG Research	Buy
Dec-16-22	Upgrade	UBS	Neutral → Buy
Apr-04-22	Resumed	Cantor Fitzgerald	Overweight
Jan-05-22	Reiterated	Needham	Buy
Dec-09-21	Upgrade	Oppenheimer	Perform → Outperform
Nov-05-21	Upgrade	JP Morgan	Neutral → Overweight
Sep-15-21	Upgrade	Guggenheim	Neutral → Buy
Aug-05-21	Upgrade	JP Morgan	Underweight → Neutral
Jun-15-21	Initiated	BTIG Research	Buy
Apr-26-21	Resumed	Credit Suisse	Neutral
Jan-12-21	Downgrade	Citigroup	Buy → Neutral
Jan-11-21	Downgrade	UBS	Buy → Neutral
Jan-08-21	Downgrade	JP Morgan	Overweight → Underweight
Jan-08-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-08-21	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-11-20	Initiated	Berenberg	Hold
Oct-28-20	Initiated	UBS	Buy
Aug-25-20	Initiated	Raymond James	Outperform
Aug-20-20	Downgrade	Credit Suisse	Outperform → Neutral
Mar-31-20	Initiated	Mizuho	Buy
Nov-01-19	Initiated	Guggenheim	Buy
Aug-21-19	Reiterated	Needham	Buy
Jul-09-19	Reiterated	Morgan Stanley	Overweight
Jul-01-19	Reiterated	RBC Capital Mkts	Outperform
Apr-12-19	Initiated	Evercore ISI	Outperform
Mar-11-19	Reiterated	Credit Suisse	Outperform
Oct-12-18	Initiated	Bernstein	Outperform
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Sep-26-18	Reiterated	RBC Capital Mkts	Outperform
Sep-14-18	Resumed	BofA/Merrill	Buy
Sep-06-18	Initiated	Credit Suisse	Outperform
Aug-01-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-21-18	Reiterated	Robert W. Baird	Outperform
Jun-20-18	Reiterated	Needham	Buy
Jun-19-18	Reiterated	H.C. Wainwright	Buy

View All

Sarepta Therapeutics Inc Stock (SRPT) Latest News

01:39 AM

A Look At Sarepta Therapeutics (SRPT) Valuation After Elevidys Launch Updates And Recovery Story Analyst Commentary - simplywall.st

01:39 AM

Mar 04, 2026

SRPT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 04, 2026

Mar 03, 2026

Jefferies Maintains Buy on Sarepta Therapeutics (SRPT) March 03, 2026 - Meyka

Mar 03, 2026

Sarepta (SRPT) COO Estepan reports PSU vesting and tax share withholding - Stock Titan

Mar 03, 2026

SRPT: 2026 revenue targets remain solid as clinical and commercial initiatives advance toward 2027 - TradingView

Mar 03, 2026

SRPT SEC FilingsSarepta Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 03, 2026

Sarepta Therapeutics’ 2025 Restructuring Plan Faces High Execution Risk Amid Deep Job Cuts and Cost-Saving Uncertainty - TipRanks

Mar 03, 2026

Decoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT Insight - GuruFocus

Mar 03, 2026

Mar 02, 2026

Sarepta Therapeutics Eyes 2026 Reset After Rocky Year - TipRanks

Mar 02, 2026